Under construction – not a live service
Sign in
Taking people in BelgiumNo phase

Using ultrasound through the endoscope to track beta-blocker response in cirrhosis

Tests whether an endoscopic ultrasound measure guides beta-blocker treatment in adults with cirrhosis.

Key facts

Who runs it
Universitaire Ziekenhuizen KU Leuven
Where
Leuven, BelgiumSee the site
Trial code
Registry title
EUS-guided Response Assessment to NSBB
Status
Recruiting
People taking part
24 people, planned
Started
17 Jul 2024
Expected to end
Dec 2026
Type of study
Interventional
Treatments tested
  • endoscopic ultrasound-guided portal pressure measurement
Record updated
3 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with compensated cirrhosis who may have clinically significant portal hypertension and need non-selective beta-blocker treatment. They must not be on this treatment yet.

Age
18 to 80 years
Sex
All sexes
Disease stage
Compensated cirrhosis with suspected clinically significant portal hypertension (CSPH).
Earlier treatment
Not yet on non-selective beta-blocker (NSBB) therapy.

Main reasons for not taking part

  • Liver cancer (HCC), portopulmonary hypertension, or blood clots in the portal or splanchnic veins
  • Previous TIPS or liver transplant
  • Pregnant, breast-feeding, or planning pregnancy during the study
  • INR >1.7 or platelet count <50.000 per mm3
  • Systolic BP <100 mmHg or HR <50 bpm

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Patients with a clinical and/or pathological diagnosis of compensated cirrhosis
  • Patients with suspicion of CSPH and thus indication for NSBB treatment
  • Patients not yet on NSBB therapy
  • Patients willing and able to undergo repeated HVPG and EUS-guided pressure measurements as per protocol

Who cannot take part

  • Patients with cirrhosis and HCC Portopulmonary hypertension Portal or splanchnic venous thrombosis Prior TIPS Prior liver transplantation
  • Previous total or partial splenectomy
  • Patients with contraindications for non-selective beta-blocker therapy, including but not limited to the following baseline vital signs:; Systolic BP <100 mmHg HR <50 bpm
  • Non-cirrhotic portal hypertension or pre-sinusoidal liver disease
  • Known infection that is not controlled by medical intervention
  • Diagnosis of portal vein thrombosis during EUS
  • Evidence of active gastrointestinal bleeding during EUS
  • Cholestatic liver disease with total bilirubin >3 mg/dl
  • INR >1.7 or platelet count <50.000 per mm3
  • eGFR <50 ml/min/1.73m2 (CKD-EPI formula) Anatomical criteria
  • Patient is <18 or >80 years of age
  • General criteria
  • Patient is pregnant, breast-feeding or planning to become pregnant during the course of the study
  • Patient is unwilling or unable to sign the informed consent
  • Patients in whom general anesthesia or endoscopic procedures are contraindicated Medical criteria
  • Patients with reduced life expectancy described by an ASA score of 4 or 5
  • Anatomical abnormalities that prevent access via EUS-guided puncture to the hepatic vein or intrahepatic portion of the portal vein, including anatomy that predisposes to difficult to reach puncture sites or an inadequate needle angle
  • Visualization of ascites interposing the puncture tract on EUS

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in Belgium

  • University Hospital LeuvenLeuven, BelgiumContact: Emma Vanderschueren, MDTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if endoscopic ultrasound (EUS)-guided portal pressure measurement can determine the treatment response to non-selective beta-blockers (NSBB) in patients with cirrhosis and clinically significant portal hypertension (CSPH). Participants will undergo EUS-guided portal pressure measurement before start of Carvedilol en after three months of treatment. EUS-guided measurements will be paired with transjugular hepatic venous pressure gradient (HVPG) measurement as well as non-invasive tests for assessment of portal hypertension.

The group in the trial

  • EUS-PPG before and after NSBBTreatment being tested

    Patients will undergo EUS-PPG and HVPG before and after NSBB treatment and will thus serve as their own control.

    Treatment: endoscopic ultrasound-guided portal pressure measurement

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Endoscopic Ultrasound Guided Response Assessment to Non-selective Beta-blockers in the Treatment of Clinically Significant Portal Hypertension
Plain-language title
Using ultrasound through the endoscope to track beta-blocker response in cirrhosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06513195, who can take part
Record updated
3 June 2026